A Phase II Study of Intermittent Recombinant Human Interleukin-2 (rhIL-2) by Intravenous or Subcutaneous Administration in Subjects With HIV Infection on Highly Active Antiretroviral Therapy (HAART) Compared to HAART Alone
This study has been completed.
Study NCT00000870
Information provided by National Institute of Allergy and Infectious Diseases (NIAID)
First Received: November 2, 1999
Last Updated: December 19, 2008
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
